LOL, laraz, this is fun. Lets take a look.
Its been 865 days since Prolanta has been in phase 1 recruiting status?
Nope, that is incorrect. Oncolix updated their recruitment status in Feb 2018 to reflect the fact that a second dosing group is currently ongoing.
Phase 1 a bust?
Nope, that is incorrect. Phase 1 continues to show potential, hence the second round of dosing.
In 865 days, Oncolix is yet to furnish a provable verifiable recruit
Nope, that is incorrect. SEC documents show that there were recruits who were dosed and tested.
Just to expand on that for anyone paying attention.
Oncolix is under the scrutiny of both the SEC and the FDA for public statements and filings.
Oncolix has not addressed publically who is currently manufacturing Prolanta
Biovectra is the manufacturer for Prolanta. The former CEO of Biovectra, a subsidiary of Mallinckrodt Pharmaceuticals NYSE:MNK is on the ONCX BOD.
Now calculate how many shares were sold to Toxic Financers in the last 865 days times the ratio of PPS decline?
We have done this several times.
In the 10Q filed on 8-18-2017 for Q2 ending 6-30-2017 the ONCX O/S is 103,097,783.
In the 10Q filed on 5-14-2018, for Q1 ending 3-31-2018, the ONCX O/S is 104,477,936.
There has been very little dilution here.
We now know why.
Note holders have agreed to not only provide over $1,000,000+ in additional funding, but are deferring interest and equity repayment until April 2019, which ensures that current shareholders are not gonna be diluted until after results of FDA phase 1 dosing of the second group is public for all to see.
They are not converting, they are not dumping.
Anyone claiming otherwise is either posting false information or ignorant of the facts.
Hope that helps.
GLTU, IMO and FWIW.